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Introduction. Hepatic inflammation underlies the pathogenesis of chronic diseases such as insulin resistance and type 2 diabetes
mellitus. S-[6]-Gingerol has been shown to have anti-inflammatory properties. Important inflammatory mediators of interleukins
include nuclear factor 𝜅B (NF𝜅B) and cyclooxygenase 2 (COX2).We now explore the mechanism of anti-inflammatory effects of S-
[6]-gingerol in liver cells. Methods. HuH7 cells were stimulated with IL1𝛽 to establish an in vitro hepatic inflammatory model.
Results. S-[6]-Gingerol attenuated IL1𝛽-induced inflammation and oxidative stress in HuH7 cells, as evidenced by decreasing
mRNA levels of inflammatory factor IL6, IL8, and SAA1, suppression of ROS generation, and increasing mRNA levels of DHCR24.
In addition, S-[6]-gingerol reduced IL1𝛽-induced COX2 upregulation as well as NF𝜅B activity. Similar to the protective effects of S-
[6]-gingerol, both NS-398 (a selective COX2 inhibitor) and PDTC (a selective NF𝜅B inhibitor) suppressedmRNA levels of IL6, IL8,
and SAA1. Importantly, PDTC attenuated IL1𝛽-induced overexpression of COX2. Of particular note, the protective effect of S-[6]-
gingerol against the IL1𝛽-induced inflammatory response was similar to that of BHT, an ROS scavenger. Conclusions. The findings
of this study demonstrate that S-[6]-gingerol protects HuH7 cells against IL1𝛽-induced inflammatory insults through inhibition of
the ROS/NF𝜅B/COX2 pathway.
1. Introduction
Hepatic inflammation underlies the pathogenesis of chronic
diseases such as insulin resistance, type 2 diabetes mellitus,
atherosclerosis, and nonalcoholic fatty liver disease (NAFLD)
[1, 2]. Liver inflammation leads to the secretion of proinflam-
matory cytokines and chemokines which, in turn, contribute
to a feed-forward amplification of the inflammatory signal
and subsequent progression of these chronic diseases [3].
Nuclear factor kappa B (NF𝜅B) is the master regulator of
the hepatic inflammatory response. Under basal conditions,
NF𝜅B is present in the cytoplasm of hepatocytes in a latent
form. Upon exposure to proinflammatory stimuli, NF𝜅B is
activated and migrates to the cell nucleus where it directs
transcription of target genes [4]. These include genes encod-
ing cytokines, chemokines, and the enzyme cyclooxygenase
2 (COX2) [5]. Cyclooxygenase (COX) is among the most
important proinflammatory mediators and COX2 is respon-
sible for persistent inflammation [6].
Ginger has been known for centuries as a valuablemedici-
nal herb having anti-inflammatory properties [7, 8]. Different
studies have shown that ginger extracts suppress inflam-
mation through inhibition of the classical NF𝜅B pathway
in various cell types and tissues [9, 10]. We have recently
shown that Zingiber officinale suppressed hepatic NF𝜅B acti-
vation thereby suppressing cytokine expression from the liver
[11]. Phenolic gingerols and related compounds, which are
responsible for the pungent taste of ginger, have been a major
focus of research related to the anti-inflammatory effects of
ginger. S-[6]-Gingerol (1-[4󸀠-hydroxy-3󸀠-methoxyphenyl]-5-
hydroxy-3-decanone) is the major pungent principle of gin-
ger, with numerous pharmacological properties including
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anti-inflammatory and antioxidant properties [12–14]. How-
ever, the mechanisms that underlie the anti-inflammatory
effects of S-[6]-gingerol in cytokine-stimulated hepatocytes
remain largely unknown.
In the present study, we investigated the anti-inflamma-
tory properties of S-[6]-gingerol in HuH7 cells stimulated
by the cytokine, IL1𝛽. Our findings show that S-[6]-gingerol
protects HuH7 cells against an IL1𝛽-induced inflammatory
response by inhibiting the reactive-oxygen-species- (ROS-)
activated NF𝜅B/COX2 pathway.
2. Materials and Methods
2.1. Materials and Cell Culture. [6]-S-Gingerol (1-[4󸀠-hy-
droxy-3󸀠-methoxyphenyl]-5-hydroxy-3-decanone) was iso-
lated from total ginger extract as described previously [15].
IL1𝛽 was purchased from Bio-Scientific Pty. Ltd. (Gymea,
NSW, Australia). N-(2-Cyclohexyloxy-4-nitrophenyl)-meth-
ane sulfonamide (NS-398), pyrrolidine dithiocarbamate
(PDTC), nitroblue tetrazolium (NBT), and butylated hydrox-
ytoluene (BHT) were purchased from Sigma-Aldrich Pty.
Ltd (Castle Hill, NSW, Australia). Human hepatocyte HuH7
cells (Health Science ResearchResources Bank,Osaka, Japan)
were cultured in DMEM medium (Sigma-Aldrich, Castle
Hill, NSW, Australia) with 10% FBS (Invitrogen, Kilsyth,
Victoria, Australia) at 37∘C in 5% CO
2
.
2.2. CellTiter-Blue Cell Viability Assay. HuH-7 cells were
seeded in 96-well plate in 100 𝜇L cell culture media and
incubated for 24 hours with S-[6]-gingerol (50 𝜇M, 100 𝜇M,
and 200𝜇M) or DMSO (vehicle control). Following incu-
bation, 20𝜇L of CellTiter-Blue Reagent (Promega, Madison,
USA) was added to each well with shaking for 10 sec. After
incubation for another 2 hours, the plate was shaken for 10 sec
and the fluorescence was recorded at 560 nm and 590 nm,
respectively, according to the manufacture’s protocol.
2.3. Transient Cell Transfections and LuciferaseMeasurements.
HuH7 cells were transfected using Effectene (Qiagen, Hilden,
Germany) with NF𝜅B-luciferase reporter vector and pRL-
TK for transfection control (Promega Corporation, Madison,
WI, USA), as previously described [16]. The transfected cells
were preincubatedwith S-[6]-gingerol for 6 h then stimulated
with IL1𝛽 for 3 h. Luciferase and Renilla activities were
detected by assaying cell lysates using the Dual-Luciferase
Reporter System (Promega), according to the manufacturer’s
protocol.
2.4. RT-qPCR. Total RNA was extracted from HuH7 cells
using TRI reagent (Sigma-Aldrich), and the concentration
was normalized to 100 ng/𝜇L using Nanoveu (LifeScience).
cDNA was generated from 100 ng of total RNA using
iSCRIPT (BioRad, Regents Park, NSW, Australia). An aliquot
of each cDNA sample (1𝜇L) was amplified by real-time PCR
in reaction mixtures containing primers (12 pmol each) and
iQSYBRGreen Supermix (BioRad). Sequences of the primers
used in the real-time PCR reaction were as follows: human
IL-6 forward: 5󸀠-CAAATTCGGTACATCCTCGACGGC,
reverse: 5󸀠-GGT TCA GGT TGT TTT CTG CCA GTG C;
human IL-8 forward: 5󸀠-CGG AAG GAA CCA TCT CAC
TGT, reverse: 5󸀠-GGT CCA CTC TCA ATC ACT CTC A;
human SAA1 forward: 5󸀠-CCA ATC ACT TCC GAC CTG
CTG, reverse: 5󸀠-GCT TTG TAT CCC TGC CCT GAG;
human𝛽2-microglobulin (B2M) forward: 5󸀠-CATCCAGCG
TAC TCC AAA GA, reverse: 5󸀠-GAC AAG TCT GAA TGC
TCC AC. DHCR24 PCR primers were purchased from Qia-
gen Pty Ltd (Doncaster, VIC, Australia). Amplification was
performed in a BioRad iQ5 thermocycler (BioRad) using the
following protocol: 95∘C for 30 sec, 𝑇
𝑚
of specific primer sets
for 30 sec, and 72∘C for 30 sec. Relative changes in mRNA
levels were determined by the ΔΔCT method [17], using
human B2M as the reference gene.
2.5. Measurement of Intracellular ROS Generation. NBT
reduction assay was used to measure intracellular superoxide
anion. HuH7 cells were seeded in 12-well plates. After treat-
ment, cells were washed with Hanks balanced salt solution
(HBSS, Sigma-Aldrich) and then incubated in Krebs-Hensel-
eit buffer (Sigma-Aldrich) containing 1mg/mL NBT for 1 h
at 37∘C. Cells were then washed with HBSS and lysed with
phosphate buffer (80mM, pH 7.8) containing sodium dode-
cyl sulfate (SDS) and gelatin. The cell lysate was centrifuged
for 5min at 13,000×g and the absorbance measured at
540 nm (formazan) and 450 nm. The relative concentration
of superoxide anion was calculated based on the amount of
formazan formed according to the standard curve.
2.6. Statistical Analysis. Data are expressed as mean ± SEM.
Differences between two different conditions were deter-
mined by one-way ANOVA with Bonferroni’s posttest anal-
ysis used to determine significance. GraphPad PRISM Soft-
ware Version 4.03 (GraphPad Software, Inc., San Diego, CA)
was used for analyses. Significance was set at 𝑃 < 0.05.
3. Results
3.1. Cell Viability. To determine if S-[6]-gingerol affected cell
viability at the concentration used in the study, cell viability
assays were performed. HuH-7 cells were treated with 50𝜇M,
100 𝜇M, or 200𝜇M S-[6]-gingerol for 24 hours, and cell
viabilitywas determinedusing theCellTiter-Blue cell viability
assay. Figure 1 demonstrated that up to 100 𝜇M S-[6]-gingerol
did not have a cytotoxic effect for 24 hours with a 6.88± 1.06%
decrease in cell viability compared to DMSO vehicle control
(𝑃 > 0.05).
3.2. S-[6]-Gingerol Suppresses IL1𝛽-Induced Inflammatory
Cytokine Expression in HuH7 Cells. To investigate the effect
of S-[6]-gingerol on IL1𝛽-induced inflammation, mRNA lev-
els of cytokines IL6, IL8, and SAA1 were determined by real-
time PCR. After exposure of HuH7 cells to 8 ng/mL IL1𝛽 for
3 h, mRNA levels of IL6 (Figure 2(a)), IL8 (Figure 2(b)), and
SAA1 (Figure 2(c)) were significantly increased. Pretreatment
with 100 𝜇M S-[6]-gingerol for 6 h before exposure to IL1𝛽
markedly suppressed IL6 (Figure 2(a)), IL8 (Figure 2(b)),
















Figure 1: 100 𝜇M S-[6]-gingerol is not toxic to HuH-7 cells. HuH-7
cells were exposed to S-[6]-gingerol (G) at different concentrations
(50𝜇M, 100 𝜇M, and 200𝜇M) for 24 hours, and cell viability was
determined using the CellTiter-Blue cell viability assay. Results are
expressed as mean ± SEM of 3 independent experiments, relative to
DMSO vehicle control. ∗𝑃 < 0.05 versus DMSO vehicle control.
and SAA1 (Figure 2(c)) mRNA levels in HuH7 cells, respec-
tively. These results suggest that S-[6]-gingerol has an anti-
inflammatory effect in IL1𝛽-stimulated HuH7 cells.
3.3. S-[6]-Gingerol Inhibits IL1𝛽-Induced Oxidative Stress in
HuH7 Cells. To determine the effect of S-[6]-gingerol on
IL1𝛽-induced oxidative stress, intracellular superoxide and
DHCR24 levels were measured. Exposure of HuH7 cells to
8 ng/mL IL1𝛽 for 3 h led to a noticeable increase in superoxide
generation (Figure 3(a)). Pretreatment with 100𝜇M S-[6]-
gingerol for 6 h prior to IL1𝛽 exposure decreased intracellular
superoxide levels in HuH7 cells. Additionally, treatment of
HuH7 cells with 8 ng/mL IL1𝛽 for 3 h significantly decreased
DHCR24 mRNA levels (Figure 3(b)), indicating that IL1𝛽
treatment impairs cellular defense mechanisms. Importantly,
pretreatment with 100 𝜇M S-[6]-gingerol attenuated the
inhibitory effect of IL1𝛽 on DHCR24 levels in HuH7 cell.
These findings suggest that S-[6]-gingerol exerts an antiox-
idative effect on IL1𝛽-stimulated HuH7 cells.
3.4. Downregulation of Induced COX2 Contributes to the Anti-
Inflammatory Effects of S-[6]-Gingerol in IL1𝛽-Stimulated
HuH7 Cells. After treatment of HuH7 cells with 8 ng/mL
IL1𝛽 for 3 h, expression of COX2 was significantly increased.
Pretreatment with 100𝜇M S-[6]-gingerol for 6 h attenuated
the upregulation of COX2 mRNA levels induced by IL1𝛽
(Figure 4(a)). Furthermore, pretreatment with 100𝜇M NS-
398, a selective inhibitor of COX2, for 30min before exposure
to IL1𝛽 also inhibited mRNA levels of IL6, IL8, and SAA1
(Figure 5). These findings suggest that inhibition of IL1𝛽-
induced COX2 expression is involved in the protective effect
of S-[6]-gingerol in HuH7 cells.
3.5. S-[6]-Gingerol Inhibits IL1𝛽-Induced NF𝜅B Activation in
HuH7 Cells. Exposure of HuH7 cells to 8 ng/mL IL1𝛽 for 3 h
significantly enhanced NF𝜅B activity (Figure 4(b)). Pretreat-
ment of HuH7 cells with S-[6]-gingerol for 6 h significantly
inhibited IL1𝛽-induced NF𝜅B activity. In keeping with this
result, pretreatment with 50𝜇M PDTC, a selective inhibitor
of NF𝜅B, for 30min before exposure to IL1𝛽 abrogated IL1𝛽-
induced COX2, IL6, IL8, and SAA1 expression (Figures 6(a)
and 5). Together, these results suggest that the protective
effects of S-[6]-gingerol against IL1𝛽-induced inflammation
are, at least in part, associated with inhibition of NF𝜅B
activation in HuH7 cells.
3.6. Inhibition of Oxidative Stress Is Involved in the Protection
of S-[6]-Gingerol against Inflammation in IL1𝛽-Stimulated
HuH7 Cells. Decreasing oxidative stress underlies anti-
inflammatory effects [18]. We therefore next compared the
effect of BHT, an ROS scavenger, with S-[6]-gingerol in
their ability to suppress IL1𝛽-induced IL6, IL8, and SAA1
expression. As expected BHT did decrease mRNA levels
of IL6, IL8, and SAA1, and we found that S-[6]-gingerol
was equally effective (Figure 5). Furthermore, it was shown
that similar to S-[6]-gingerol, pretreatment with 50𝜇M BHT
inhibited IL1𝛽-inducedCOX2 upregulation (Figure 6(a)) and
NF𝜅B activity (Figure 6(b)) in HuH7 cells. The previous
results indicate that suppressed ROS levels may contribute
to the protective effects of S-[6]-gingerol against the IL1𝛽-
induced inflammatory response in HuH7 cells.
4. Discussion
The present study demonstrates that S-[6]-gingerol has the
potential to protect hepatocytes against IL1𝛽-induced inflam-
matory response. Moreover, for the first time, we show
that S-[6]-gingerol achieves its potent anti-inflammatory
effects through inhibition of an ROS-activated NF𝜅B/COX2
pathway. These results may explain how ginger improved
insulin resistance in high-fat diet rat in our previous study
[11].
COX2 has an important role in the inflammatory process.
There is extensive evidence based on in vivo and in vitro
models of inflammation that COX2 and COX2-induced
production of prostaglandins (PGs) are involved in inflam-
mation. Animal models of inflammation have demonstrated
that an increase in COX2 mRNA and protein, as well as
PG levels, parallels the inflammatory process [19]. COX2
specific inhibitors andmonoclonal antibody to prostaglandin
E2 (PGE2) have been shown to control inflammation [20, 21].
A study on chronic liver disease has shown that endoplasmic
reticulum stress induced by hepatitis B virus X protein (HBx)
enhanced COX2 expression in HBx transgenic mice and in
the HuH7 cells that were transfected with HBx expression
plasmid [22]. COX2 is usually absent under basal con-
ditions, but it is inducible by various cytokines, growth
factors, and mitogens [23–26]. It has been shown that the
inducible COX2 is not only responsible for production of
PGs in response to inflammation [24, 25], but also a potent
proinflammatory mediator that promotes the production
of proinflammatory cytokines including IL6 and IL1𝛽 [27].
Treatment with a selective COX2 inhibitor blocks the secre-
tion of proinflammatory cytokines IL6, IL1𝛽, and IL8 induced


































































Figure 2: S-[6]-Gingerol decreases IL1𝛽-induced inflammatory factors expression in HuH7 cell. HuH7 cells were pretreated with 100 𝜇M
S-[6]-gingerol (G) or DMSO (vehicle control) for 6 h then stimulated with IL1𝛽 (8 ng/mL) for 3 h. The mRNA levels of IL6 (a), IL8 (b), and
SAA1 (c) were measured using RT-qPCR, normalised to B2M. Results are expressed as mean ± SEM of 3 independent experiments, relative
to DMSO controls. ∗𝑃 < 0.05 versus DMSO vehicle control; #𝑃 < 0.05 versus IL1𝛽 treatment.
by cobalt chloride (CoCl
2
) in human skin keratinocytes
[28].
Due to its proinflammatory effects, COX2 is a chief target
for the treatment of inflammation. For example, the ther-
apeutic effects of the nonsteroidal anti-inflammatory drug,
aspirin, target the selective inhibition of COX2 [29]. Based
on previous studies that have used IL1𝛽-stimulated HuH7
liver cells [30–32], we too established this in vitro hepatocyte
cell inflammatorymodel to investigate the anti-inflammatory
mechanisms of S-[6]-Gingerol. Themarkers of inflammation
that we tested were IL6, IL8, and SAA1, all known drivers
or biomarkers of liver inflammation [33, 34]. Our results
show that S-[6]-gingerol attenuated IL1𝛽-induced COX2
expression in HuH7 cells, associated with a decrease in the
expression of IL6, IL8, and SAA1. We also show that the level
of inhibition achieved by S-[6]-gingerol for inhibition of the
expression of IL6, IL8, and SAA1 was similar to that mediated
by the COX2 inhibitor. Together, these data suggest that
COX2 is most likely a central player in mediating the anti-
inflammatory effects of S-[6]-gingerol.
Hepatic inflammation can drive insulin resistance and
the key mediator of the inflammatory response is NF𝜅B [3].
Activated hepatic NF𝜅B alone can drive insulin resistance
as transgenic expression of the I𝜅B kinase (IKK𝛽) results in
overt insulin resistance in mice fed a normal chow diet [3].
By contrast, when heterozygous IKK𝛽+/− mice that express
low levels of NF𝜅B are fed a high-fat diet or are crossed
with obese ob/obmice, they do not develop insulin resistance
[35]. Moreover, NF-𝜅B inhibition by abrogation of liver IKK
activity directly protects against insulin resistance in response
to a high-fat diet in mice [36]. Together, these studies suggest
that the liver is a primary site of inflammatory action respon-
sible for the development of insulin resistance and that NF𝜅B
is a central pathogenic factor underlying inflammation-
induced insulin resistance. Our results show that S-[6]-
gingerol inhibited IL1𝛽-induced NF𝜅B activation in HuH7
cells. We also show that the ability of S-[6]-gingerol to
suppress the expression of COX2 and IL8 was the same
order of magnitude induced by treatment with the NF𝜅B
inhibitor, while S-[6]-gingerol also significantly suppressed















































Figure 3: S-[6]-Gingerol inhibits IL1𝛽-induced oxidative stress in HuH7 cells. HuH7 cells were pretreated with 100 𝜇M S-[6]-gingerol (G)
or DMSO (vehicle control) for 6 h then stimulated with IL1𝛽 (8 ng/mL) for 3 h. (a) The levels of ROS generation were measured using the
NBT reduction assay. The relative concentration of ROS was calculated based on the generated amount of formazan. (b)The mRNA levels of
DHCR24 were measured using RT-qPCR, normalised to B2M. Results are expressed as mean ± SEM of 3 independent experiments, relative












































Figure 4: S-[6]-Gingerol suppresses IL1𝛽-induced COX2 expression and NF𝜅B activity in IL1𝛽-stimulated HuH7 cells. (a) HuH7 cells were
pretreated with 100 𝜇M S-[6]-gingerol (G) or DMSO (vehicle control) for 6 h then stimulated with IL1𝛽 (8 ng/mL) for 3 h. The mRNA levels
of COX2 were measured using RT-qPCR, normalised to B2M. (b) HuH7 cells were transfected with the NF𝜅B-luciferase reporter vector.
Transfectants were preincubated for 6 h with 100𝜇M S-[6]-gingerol (G) or DMSO (vehicle control) and then stimulated with IL1𝛽 for 3 h.
Cells were then harvested and cell lysates assayed for luciferase activity. Results are expressed as mean ± SEM of 3 independent experiments,
relative to the DMSO vehicle controls. ∗𝑃 < 0.05 versus DMSO vehicle control; #𝑃 < 0.05 versus IL1𝛽 treatment.
IL6 and SAA1 mRNA levels. These data suggest that NF𝜅B
is involved in mediating the anti-inflammatory effects of S-
[6]-gingerol.
It is well recognized that inflammation is one man-
ifestation of oxidative stress [37], and the pathways that
generate the inflammatory factors, such as cytokines, are all
induced by oxidative stress [37]. The present study shows
that S-[6]-gingerol decreased superoxide production in IL1𝛽-
stimulated HuH7 cells. We also show that the ability of
S-[6]-gingerol to inhibit IL1𝛽-induced NF𝜅B activation and
suppress the expression of COX2 and IL6, IL8, and SAA1
paralleled the results we obtained when we treated the cells
with the ROS scavenger, BHT. Our results also show that S-
[6]-gingerol increased the expression of antioxidant enzyme,
DHCR24. Given that antioxidant enzymes are able to block
NF𝜅B activation by various stimuli [38–44], our findings
suggest that the anti-inflammatory effects of S-[6]-gingerol
are mediated, at least in part, by suppressing oxidative stress.
One limitation of this study is that the mechanisms
of anti-inflammatory effects of S-[6]-gingerol demonstrated
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Figure 5: Comparison of the effects of S-[6]-gingerol with those of selective inhibitors on increased IL6, IL8, and SAA1 expression induced by
IL1𝛽 in HuH7 cells. Before treatment with IL1𝛽 (8 ng/mL) for 3 h, HuH7 cells were pretreated with 100𝜇M S-[6]-gingerol (G) for 6 h, or with
100𝜇M NS398, 50 𝜇M PDTC, or 50𝜇M BHT for 30min. The mRNA levels of IL6 (a), IL8 (b), and SAA1 (c) were detected using RT-qPCR,
normalized to B2M. Results are expressed as mean ± SEM of 3 independent experiments, relative to DMSO controls. ∗P < 0.05 versus DMSO
vehicle control; #𝑃 < 0.05 versus IL1𝛽 treatment.
here are restricted to in vitro evidence. However, the results
with the human hepatocyte cell line support previous find-
ings in an animal model to demonstrate that the anti-
inflammatory effect of Zingiber officinale (ginger) occurs
through the NF𝜅B signalling pathway [11] and now define
a mechanism of anti-inflammatory effects of S-[6]-gingerol
through inhibition of cytokine IL1𝛽-induced ROS/NF𝜅B/
COX2 pathway that was not possible with the animal model.
In conclusion, S-[6]-gingerol has been shown to inhibit
IL6, IL8, and SAA1 expression in cytokine-stimulated
HuH7 cells, via suppression of COX2 expression. We have
also shown that the suppression of COX2 is achieved via
blockade of the NF𝜅B signalling pathway. Finally, we have
shown that S-[6]-gingerol blocks the NF𝜅B/COX2 path-
way through suppressing the cytokine-induced oxidative
stress.These resultsmay opennovel treatment optionswhere-
by S-[6]-gingerol could potentially protect against hepatic
inflammation which underlies the pathogenesis of chronic
diseases such as insulin resistance and type 2 diabetes
mellitus.
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Figure 6: Comparison of the effects of S-[6]-gingerol with those of
selective inhibitors on IL1𝛽-induced COX-2 expression and NF𝜅B
activity in HuH7 cells. (a) Before treatment with IL1𝛽 (8 ng/mL) for
3 h, HuH7 cells were pretreated with 100𝜇M S-[6]-gingerol (G) for
6 h, or with 50 𝜇M PDTC or 50𝜇M BHT for 30min. The mRNA
levels of COX2 were detected using RT-qPCR, normalized to B2M.
(b) HuH7 cells were transfected with the NF𝜅B-luciferase reporter
vector. Before treatment with IL1𝛽 (8 ng/mL) for 3 h, transfected
HuH7 cells were pretreated with 100𝜇M S-[6]-gingerol (G) for 6 h,
or with 50 𝜇M BHT for 30min. Cells were then harvested and cell
lysates assayed for luciferase activity. Results are expressed as mean
± SEM of 3 independent experiments, relative to the DMSO vehicle
controls. ∗𝑃 < 0.05 versus DMSO vehicle control; #𝑃 < 0.05 versus
IL1𝛽.
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